Cyclo Therapeutics, Inc. (CYTHW) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: March 26, 2025
Cyclo Therapeutics, Inc. (CYTHW) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Cyclo Therapeutics, Inc. (Stock Symbol: CYTHW)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $7 million - Classified as a
small-cap investment offering high growth potential.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Cyclo Therapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Cyclo Therapeutics, Inc. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
The company maintains a healthy 179.4% gross margin, indicating strong pricing power and operational efficiency.
Cyclo Therapeutics, Inc. Stock Price Chart and Technical Analysis
Loading chart data...
Loading Cyclo Therapeutics, Inc. interactive price chart and technical analysis...
Deep dive into Cyclo Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Cyclo Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Cyclo Therapeutics, Inc.:
P/B Ratio-0.49x
Market Cap$7M
Book Value/Share$-0.47
Revenue/Share$0.01
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Cyclo Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Cyclo Therapeutics, Inc.:
Gross Margin179.4%
Operating Margin-8299.7%
Net Margin-8337.0%
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Cyclo Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Cyclo Therapeutics, Inc.:
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Cyclo Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Cyclo Therapeutics, Inc.:
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Cyclo Therapeutics, Inc. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Cyclo Therapeutics, Inc.:
Understanding Financial Statement Data
What these metrics mean: Key figures from Cyclo Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Cyclo Therapeutics, Inc.:
Income Statement ($ Millions)
Operating Income$-24M
Net Income$-24M
R&D Expense$16M
Cost of Goods Sold$0M
Balance Sheet Highlights ($ Millions)
Dividend & Shareholder Information
Shares Outstanding29M
Cyclo Therapeutics, Inc. (CYTHW) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Cyclo Therapeutics, Inc. stock analysis.
Loading fundamental data...
Loading Cyclo Therapeutics, Inc. comprehensive fundamental analysis and insider trading data...
Latest Cyclo Therapeutics, Inc. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting Cyclo Therapeutics, Inc. (CYTHW) stock price and investment outlook.
Investor Contact: Cyclo Therapeutics, Inc. JTC Team, LLC Jenene Thomas (833) 475-8247 CYTH@jtcir.com Applied Molecular Transport Inc. Wheelhouse Life Science Advisors Alexandra Santos asantos ...
Cyclo Therapeutics, Inc. met with FDA in the February 2020 to discuss the design of the Phase III global pivotal trial and expects to meet with EMA for the same purpose in the second quarter of 2020.
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL) May 02, 2023 08:12 AM Eastern Daylight Time ...
At the time of writing, our data shows that Cyclo Therapeutics, Inc. has a market capitalization of US$17m, and reported total annual CEO compensation of US$490k for the year to December 2019.
Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the ...
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and ...
Cyclo Therapeutics, Inc. (NASDAQ:CYTH) is a clinical-stage biotechnology company, thriving to develop life-changing medicines aimed at patients with challenging diseases.
Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025 GAINESVILLE, Fla., January 14, 2025--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical ...
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options.
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease.
We recently compiled a list of the 10 Best Micro Cap Stocks to Buy Now. In this article, we are going to take a look at where Cyclo Therapeutics, Inc. (NASDAQ:CYTH) stands against the other micro ...
GAINESVILLE, Fla. & SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on ...
Cyclo Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of Cyclo Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - Cyclo Therapeutics, Inc. Stock Forecast
How accurate are Cyclo Therapeutics, Inc. stock predictions?
Our AI model demonstrates 19% historical accuracy for CYTHW predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Cyclo Therapeutics, Inc. stock price forecasts?
Is Cyclo Therapeutics, Inc. a good investment in 2025?
Based on our AI analysis, Cyclo Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Cyclo Therapeutics, Inc. forecasts updated?
Cyclo Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Cyclo Therapeutics, Inc. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Cyclo Therapeutics, Inc. stock.
